Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14994336 | 0.81 | — | — | |
| SCHEMBL190709 | 0.80 | NUDT1 (0.32) | — | |
| SCHEMBL16792284 | 0.80 | — | — | |
| SCHEMBL1180408 | 0.77 | KDM4E (0.36) | — | |
| SCHEMBL336342 | 0.77 | GRM5 (0.30) | — | |
| SCHEMBL2724051 | 0.77 | — | — | |
| SCHEMBL1502646 | 0.76 | CYP19A1 (0.31) | — | |
| SCHEMBL16048028 | 0.76 | MEN1 (0.32) | MEN1KMT2A | |
| SCHEMBL19454689 | 0.75 | MEN1 (0.33) | MEN1KMT2A | |
| SCHEMBL290041 | 0.74 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170152239-A1 | BENZAMIDE AND HETEROBENZAMIDE COMPOUNDS | PFIZER INC. (US) | 2017-06-01 | — | — | US | disclosed |
| US-9493478-B2 | Fused ring compound containing furan or salt thereof and pharmaceutical composition comprising same | YUHAN CORPORATION (KR) | 2016-11-15 | — | — | US | disclosed |
| US-20150239842-A1 | BENZAMIDE AND HETEROBENZAMIDE COMPOUNDS | PFIZER INC. (US) | 2015-08-27 | — | — | US | disclosed |
| EP-2414369-B1 | IMIDAZO[2,1-B][1,3,4]THIADIAZOLE DERIVATIVES | FUNDACIÓN CT NAC DE INVESTIGACIONES ONCOLÓGICAS CARLOS III (ES) | 2015-08-12 | — | — | EP | disclosed |
| EP-2900653-A1 | BENZAMIDE AND HETEROBENZAMIDE COMPOUNDS | Pfizer Inc. (US) | 2015-08-05 | — | — | EP | disclosed |
| US-20150191478-A1 | FUSED RING COMPOUND CONTAINING FURAN OR SALT THEREOF AND PHARMACEUTICAL COMPOSITION COMPRISING SAME | YUHAN CORPORATION (KR) | 2015-07-09 | — | — | US | disclosed |
| EP-2876109-A1 | FUSED RING COMPOUND CONTAINING FURAN OR SALT THEREOF AND PHARMACEUTICAL COMPOSITION COMPRISING SAME | Yuhan Corporation (KR) | 2015-05-27 | — | — | EP | disclosed |
| US-8815918-B2 | Imidazo [2, 1-B] [1, 3, 4] thiadiazole derivatives | CENTRO NACIONAL DE INVESTIGACIONES ONCOLOGICAS (CNIO) (ES) | 2014-08-26 | — | — | US | disclosed |
| US-20120094996-A1 | Imidazo [2, 1-B] [1, 3, 4] Thiadiazole Derivatives | CENTRO NACIONAL DE INVESTIGACIONES ONCOLOGICAS (CNIO) (ES) | 2012-04-19 | — | — | US | disclosed |
| EP-2414369-A1 | IMIDAZO [2, 1-B][ 1, 3, 4]THIADIAZOLE DERIVATIVES | Centro Nacional de Investigaciones Oncológicas (CNIO) (ES) | 2012-02-08 | — | — | EP | disclosed |
| WO-2010112874-A1 | IMIDAZO [2, 1-B] [ 1, 3, 4 ] THIADIAZOLE DERIVATIVES | CENTRO NACIONAL DE INVESTIGACIONES ONCOLOGICAS (CNIO) (ES) | 2010-10-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120094996-A1 | Imidazo [2, 1-B] [1, 3, 4] Thiadiazole Derivatives | PIK3CA, PI4KA, PIK3CD | MEN1 1819/4885KMT2A 2527/4885 |
| US-20150191478-A1 | FUSED RING COMPOUND CONTAINING FURAN OR SALT THEREOF AND PHARMACEUTICAL COMPOSITION COMPRISING SAME | PIK3CD, PIK3CA, MTOR | MEN1 1821/4885KMT2A 3492/4885 |
| US-20150239842-A1 | BENZAMIDE AND HETEROBENZAMIDE COMPOUNDS | HRH2, H1-0, H1-2 | MEN1 1508/4885KMT2A 467/4885 |
| US-20170152239-A1 | BENZAMIDE AND HETEROBENZAMIDE COMPOUNDS | HRH2, HRH4, H1-0 | MEN1 1357/4885KMT2A 376/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.